Structure-Guided Discovery of a Nonpeptidic MT5-MMP Inhibitor

Read full text
Authors: Antoine Magniez, Johanna Giovannini, Pauline Zipfel, Chloé Rémondin, Hassiba Saïdoun, Audrey Davis, Santiago Rivera, Patrick Dallemagne, Christophe Rochais, Alban Lepailleur
Cited by: 1
References: 41

Abstract

Membrane type 5-matrix metalloproteinase (MT5-MMP, MMP-24), an η-secretase involved in amyloid precursor protein processing, is a promising but unexplored target in Alzheimer’s disease. We report here the identification of a first nonpeptidic hit for MT5-MMP through a structure-guided approach. A homology model of the MT5-MMP catalytic domain was built from the MT3-MMP/batimastat structure and validated by both docking and experimental inhibition data obtained with batimastat (IC 50 = 3 nM). To account for binding-site plasticity, especially that of the S1’ pocket, molecular dynamics and ensemble docking were applied to a zinc-binding group (ZBG)-focused library of 3851 compounds. Although the initial screening campaign yielded only weakly active candidates, analysis of docking poses identified a relevant scaffold for optimization. Replacement of a carboxylic acid ZBG by a hydroxamic acid led to compound 17, which inhibited MT5-MMP with an IC 50 of 6 μM and established a first nonpeptidic hit for future optimization.

Fields of Study & Subjects

Protease and Inhibitor Mechanisms Alzheimer's disease research and treatments Catalytic Cross-Coupling Reactions

Publication details

Journal / source
ACS Medicinal Chemistry Letters
Publisher
American Chemical Society (ACS)
Volume
17
Issue
6
Pages
1407–1415
Publication date
25 May 2026
Language
EN